Targeting multidrug resistant Staphylococcus aureus with cationic chlorpromazine-peptide conjugates
© 2023 Wiley-VCH GmbH..
Antimicrobial resistance is a serious public health risk. Its severity is fueled on an unprecedented scale, necessitating the demand for novel antimicrobial scaffolds aimed at novel targets. Herein, we present cationic chlorpromazine peptide conjugates that are rationally intended to targetmultidrug-resistant (MDR) bacteria. The most potent compound, CPWL, of all the conjugates evaluated, showed promising antibacterial activity against clinical, MDR S. aureus, with no cytotoxicity. The molecular docking experiments confirmed that CPWL possessed a very high affinity for S. aureus enoyl reductase (saFabI). Furthermore, CPWL antibacterial action against saFabI was further corroborated by MD simulation studies. Thus, our findings highlight cationic chlorpromazine as a promising scaffold for the development of saFabI inhibitors to target severe staphylococcal infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Chemistry, an Asian journal - 18(2023), 10 vom: 16. Mai, Seite e202300169 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Panjla, Apurva [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 17.05.2023 Date Revised 17.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/asia.202300169 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355754851 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355754851 | ||
| 003 | DE-627 | ||
| 005 | 20231226065019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/asia.202300169 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355754851 | ||
| 035 | |a (NLM)37071585 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Panjla, Apurva |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting multidrug resistant Staphylococcus aureus with cationic chlorpromazine-peptide conjugates |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.05.2023 | ||
| 500 | |a Date Revised 17.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley-VCH GmbH. | ||
| 520 | |a Antimicrobial resistance is a serious public health risk. Its severity is fueled on an unprecedented scale, necessitating the demand for novel antimicrobial scaffolds aimed at novel targets. Herein, we present cationic chlorpromazine peptide conjugates that are rationally intended to targetmultidrug-resistant (MDR) bacteria. The most potent compound, CPWL, of all the conjugates evaluated, showed promising antibacterial activity against clinical, MDR S. aureus, with no cytotoxicity. The molecular docking experiments confirmed that CPWL possessed a very high affinity for S. aureus enoyl reductase (saFabI). Furthermore, CPWL antibacterial action against saFabI was further corroborated by MD simulation studies. Thus, our findings highlight cationic chlorpromazine as a promising scaffold for the development of saFabI inhibitors to target severe staphylococcal infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antimicrobial resistance | |
| 650 | 4 | |a antibiotics | |
| 650 | 4 | |a membrane proteins | |
| 650 | 4 | |a peptide | |
| 650 | 7 | |a Chlorpromazine |2 NLM | |
| 650 | 7 | |a U42B7VYA4P |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 700 | 1 | |a Kaul, Grace |e verfasserin |4 aut | |
| 700 | 1 | |a Akhir, Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a Saxena, Deepanshi |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Saurabh |e verfasserin |4 aut | |
| 700 | 1 | |a Modak, Chandrima |e verfasserin |4 aut | |
| 700 | 1 | |a Kumari, Dipti |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Alok |e verfasserin |4 aut | |
| 700 | 1 | |a Chopra, Sidharth |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Sandeep |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemistry, an Asian journal |d 2006 |g 18(2023), 10 vom: 16. Mai, Seite e202300169 |w (DE-627)NLM169728706 |x 1861-471X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:10 |g day:16 |g month:05 |g pages:e202300169 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/asia.202300169 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 10 |b 16 |c 05 |h e202300169 | ||